- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05004688
A Trial to Evaluate the Effects of BCG in Adults With MCI and Mild-to-Moderate AD
February 2, 2023 updated by: Steven E Arnold, MD
An Open-label Trial to Evaluate the Effects of BCG Immunization on Biomarkers of Inflammation/Immune Response and Alzheimer's Disease in Adults With Mild Cognitive Impairment and Mild-to-Moderate Dementia Due to Alzheimer's Disease
A study of the effects of Bacillus Calmette-Guérin (BCG) immunization on cerebrospinal fluid and blood-based biomarkers in older with mild cognitive impairment and mild-to-moderate to Alzheimer's disease.
Study Overview
Status
Active, not recruiting
Intervention / Treatment
Detailed Description
This single-site, open-label trial will investigate the effects of BCG vaccination on IIR and AD biofluid biomarkers, magnetic resonance imaging (MRI) biomarkers, and neurocognitive/behavioral functioning over a one year period in older adults with mild cognitive impairment (MCI) to mild-to-moderate dementia due to AD.
This study will also gather data on tolerability and safety.
Study Type
Interventional
Enrollment (Anticipated)
15
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Massachusetts
-
Charlestown, Massachusetts, United States, 02129
- Alzheimer's Clinical and Translational Research Unit
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
55 years to 85 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Individuals between the ages of 55-85;
- MCI or moderate dementia due to AD as defined by the 2011 NIA-AA Workgroup recommendations;
- MoCA ≥ 8 at screening;
- Global CDR between 0.5-2 (inclusive) at screening;
- Amyloid and/or tau biomarkers indicative of AD pathology;
- Education level, English language skills and literacy indicates subject will be able to complete all assessments;
- Has a study partner who, in the investigator's judgement, has frequent, direct contact with the participant at least several days a week, can accompany the participant to all visits, and is also able to provide information to study investigator/staff;
- Willing and able to complete all assessment and study procedures, including blood and lumbar punctures, and clinical assessments;
- If on cholinesterase inhibitor and/or memantine, doses are stable for 3 months prior to baseline;
- Negative test results for HIV antibody and Tuberculosis (QuantiFERON) at screening;
- No prior BCG exposure either through birth vaccinations (born in North American) or BCG bladder cancer treatment.
Exclusion Criteria:
- History of chronic infectious disease, such as HIV or untreated or active hepatitis;
- History of tuberculosis, positive interferon-gamma release assay (IGRA, also known as the QuantiFERON-TB test), including a test with a high reactivity to mycobacteria of non-tuberculosis variety;
- Prior BCG vaccination, positive T-spot tuberculosis test or a T-spot test showing significant Mycobacteria exposure;
- A positive SARS-CoV-2 PCR result within 3 months of screening, or known close contact with a confirmed COVID-19 positive person or symptoms highly suspicious for COVID-19 (per CDC guidelines) within 1 month of screening, including fever, cough, shortness of breath, chills, muscle pain, new loss of taste or smell, vomiting or diarrhea, and/or sore throat, based on clinician's judgment;
- History of treatment with metformin within the past one year;
- Treatment with other investigational agents which, at the discretion of the investigator, interfere with safety and/or study outcomes;
- Current treatment with immunosuppressants (calcineurin inhibitors, corticosteroids, or biological or cytotoxic immunosuppressants, or disease or condition likely to require high dose steroid or immunosuppressive therapy);
- Other conditions or treatments associated with increased risk of infections or treatment with immunosuppressive medications for any reason;
- Current treatment with aspirin > 160 mg/day or chronic, daily NSAIDs;
- Current (as of time of study screening) or chronic use of antibiotics;
- History of keloid formation;
- Living with someone who is immunosuppressed and/or at high risk for infectious diseases (for example, HIV+ or taking immunosuppressive medications for any reason), or in a job (e.g. healthcare) in which the subject works with immunosuppressed populations;
- Other/confounding neurological or psychiatric condition, unstable medical or psychiatric conditions, contraindications to BCG use and lab abnormalities or concurrent medication use posing risk for BCG or study procedures;
- Laboratory abnormalities in B12, Folate, TSH, or other common laboratory parameters that may contribute to cognitive dysfunction per clinician judgment;
- Laboratory abnormalities in CBC, electrolytes, LFTs, BUN, Cr, total serum immunoglobulins, ESR, CRP, or urinalysis posing risk to treatment with BCG per clinician judgment;
- Laboratory abnormalities in PT-INR, which would pose a risk to performing the lumbar puncture procedure;
- Discontinuation of cholinesterase inhibitor or memantine within one month (28 days) prior to baseline visit;
- Females who are pregnant, lactating or of child-bearing potential;
- If male with female partner(s) of childbearing potential, unwilling or unable to adhere to contraception requirements specified in the protocol.
- Administration of live vaccine within 30 days of screening visit or BCG immunizations
- Administration of non-live vaccine within 14 days of screening visit or BCG immunizations
- If participating in optional MRI: Existing contraindication to MRI per MGH Athinoula A. Martinos Center research guidelines
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: BCG
Active BCG immunization
|
Two Bacillus Calmette-Guérin (Japan BCG) vaccine injections spaced four week apart.
Each injection will have 0.36-3.9
x 10^6 colony forming units (CFU) reconstituted in 0.1 mL saline.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
CSF biomarkers of pharmacodynamic response- cytokines
Time Frame: Day 84
|
Change in concentration of circulating cytokines in CSF from baseline
|
Day 84
|
Blood biomarkers of pharmacodynamic response- cytokines
Time Frame: Day 84
|
Change in concentration of circulating cytokines in blood from baseline
|
Day 84
|
Cognitive Measures (RBANS)
Time Frame: Day 84
|
Change from baseline in Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) score
|
Day 84
|
Blood biomarkers of pharmacodynamic response- cytokines
Time Frame: Day 364
|
Change in concentration of circulating cytokines in blood from baseline
|
Day 364
|
CSF biomarkers of pharmacodynamic response- cytokines
Time Frame: Day 364
|
Change in concentration of circulating cytokines in CSF from baseline
|
Day 364
|
Blood biomarkers of AD pathology-ATN
Time Frame: Day 364
|
Change in concentration of ATN markers of AD pathophysiology (Amyloid-β42/40, phospho-tau, total tau and neurofilament light protein biomarkers) in blood from baseline
|
Day 364
|
CSF biomarkers of AD pathology-ATN
Time Frame: Day 364
|
Change in concentration of ATN markers of AD pathophysiology (Amyloid-β42/40, phospho-tau, total tau and neurofilament light protein biomarkers) in CSF from baseline
|
Day 364
|
Blood biomarkers of AD pathology-ATN
Time Frame: Day 84
|
Change in concentration of ATN markers of AD pathophysiology (Amyloid-β42/40, phospho-tau, total tau and neurofilament light protein biomarkers) in blood from baseline
|
Day 84
|
CSF biomarkers of AD pathology-ATN
Time Frame: Day 84
|
Change in concentration of ATN markers of AD pathophysiology (Amyloid-β42/40, phospho-tau, total tau and neurofilament light protein biomarkers) in CSF from baseline
|
Day 84
|
Cognitive Measures (RBANS)
Time Frame: Day 364
|
Change from baseline in Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) score
|
Day 364
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Steven Arnold, MD, Massachusetts General Hospital
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
March 25, 2022
Primary Completion (Anticipated)
October 1, 2023
Study Completion (Anticipated)
October 1, 2023
Study Registration Dates
First Submitted
August 6, 2021
First Submitted That Met QC Criteria
August 6, 2021
First Posted (Actual)
August 13, 2021
Study Record Updates
Last Update Posted (Actual)
February 3, 2023
Last Update Submitted That Met QC Criteria
February 2, 2023
Last Verified
February 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Mental Disorders
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Neurocognitive Disorders
- Neurodegenerative Diseases
- Tauopathies
- Cognition Disorders
- Dementia
- Alzheimer Disease
- Cognitive Dysfunction
- Physiological Effects of Drugs
- Immunologic Factors
- Adjuvants, Immunologic
- BCG Vaccine
Other Study ID Numbers
- 2021P002577
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Alzheimer Disease
-
ProgenaBiomeRecruitingAlzheimer Disease | Alzheimer Disease, Early Onset | Alzheimer Disease, Late Onset | Alzheimer Disease 1 | Alzheimer Disease 2 | Alzheimer Disease 3 | Alzheimer Disease 4 | Alzheimer Disease 7 | Alzheimer Disease 17 | Alzheimer Disease 5 | Alzheimer Disease 6 | Alzheimer Disease 8 | Alzheimer Disease 10 | Alzheimer... and other conditionsUnited States
-
Cognito Therapeutics, Inc.RecruitingCognitive Impairment | Dementia | Alzheimer Disease | Mild Cognitive Impairment | Cognitive Decline | Alzheimer Disease, Early Onset | Alzheimer Disease, Late Onset | MCI | Dementia Alzheimers | Mild Dementia | Dementia of Alzheimer Type | Cognitive Impairment, Mild | Alzheimer Disease 1 | Dementia, Mild | Alzheimer... and other conditionsUnited States
-
AphiosNot yet recruitingDementia | Alzheimer Disease 1 | Alzheimer Disease 2 | Alzheimer Disease 3
-
Capital Medical UniversityPeking University First Hospital; The First Affiliated Hospital of Anhui Medical... and other collaboratorsRecruitingAlzheimer Disease | Familial Alzheimer Disease (FAD)China
-
University of PennsylvaniaNational Institute on Aging (NIA)CompletedDementia | Alzheimer Disease, At Risk | Alzheimer Disease, Protection AgainstUnited States
-
Kyoto UniversityOsaka University; Mie University; Tokushima University; Tokyo Metropolitan Geriatric... and other collaboratorsCompletedFamilial Alzheimer Disease (FAD) | PSEN1 MutationJapan
-
University of ArizonaNational Institute on Aging (NIA); University of Southern California; Syneos... and other collaboratorsRecruitingNeurodegenerative Diseases | Alzheimer Dementia | Late Onset Alzheimer DiseaseUnited States
-
National Taiwan Normal UniversityCompletedAlzheimer Disease 2 Due to Apoe4 IsoformTaiwan
-
Northwell HealthRecruitingAlzheimer Disease | Alzheimer Disease With Delusions | Alzheimer Disease With PsychosisUnited States
-
University of Kansas Medical CenterNational Institute on Aging (NIA)CompletedHealthy Aging | Alzheimer Disease 2 Due to Apoe4 IsoformUnited States
Clinical Trials on Biological/Vaccine: Bacillus Calmette-Guerin (BCG)
-
Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.Air Force Military Medical University, China; Jiangsu Province Centers for... and other collaboratorsCompleted
-
Cadila PharnmaceuticalsCompleted
-
Verity Pharmaceuticals Inc.Not yet recruitingBladder Cancer | Urothelial Carcinoma Bladder | Bladder Cancer Recurrent | Neoplasm Recurrence | Urothelial Carcinoma Recurrent | Non-Invasive Bladder Urothelial Carcinoma
-
SWOG Cancer Research NetworkNational Cancer Institute (NCI)Active, not recruitingStage 0is Bladder Urothelial Carcinoma | Stage I Bladder Urothelial Carcinoma | Stage 0 Bladder Urothelial CarcinomaUnited States
-
Massachusetts General HospitalCompleted
-
Murdoch Childrens Research InstituteBill and Melinda Gates Foundation; Royal Children's HospitalCompletedCOVID-19 | Corona Virus Infection | Coronavirus Disease 2019 (COVID-19) | Respiratory IllnessAustralia, Brazil, Netherlands, Spain, United Kingdom
-
Mansoura UniversityRecruitingNon-Muscle Invasive Bladder CancerEgypt
-
Liverpool School of Tropical MedicineUniversity of OxfordRecruiting
-
ImmunityBio, Inc.Active, not recruitingNon Muscle Invasive Bladder CancerUnited States
-
Massachusetts General HospitalWithdrawn